Personalis Inc 2025年季度报告

OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ________ to ________Commission File Number:001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware27-5411038(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)6600 Dumbarton CircleFremont,California94555(Address of principal executive offices)(Zip Code)Registrant’s telephone number, including area code:(650)752-1300 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registeredThe Nasdaq Global Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reportingcompany☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒The number of shares of registrant’s Common Stock outstanding as of April 29, 2025 was88,325,138. PERSONALIS, INC. Form 10-QFor the Quarterly Period Ended March 31, 2025 TABLE OF CONTENTS PART I — FINANCIAL INFORMATIONItem 1.Financial Statements6Consolidated Balance Sheets6Consolidated Statements of Operations7Consolidated Statements of Comprehensive Loss8Consolidated Statements of Stockholders’ Equity9Consolidated Statements of Cash Flows10Index to Notes11Notes to Consolidated Financial Statements12Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations25Item 3.Quantitative and Qualitative Disclosures About Market Risk32Item 4.Controls and Procedures32 Item 1.Legal Proceedings33Item 1A.Risk Factors33Item 2.Unregistered Sales of Equity Securities and Use of Proceeds73Item 3.Defaults Upon Senior Securities73Item 4.Mine Safety Disclosures73Item 5.Other Information73Item 6.Exhibits74Signatures75 NOTE REGARDINGFORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectivesof management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statementsbecause they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,”“objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would” or the negative of these words or other similarterms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: •the evolution of cancer therapies and market adoption of our services and products;•estimates of our total addressable market, future revenue and the timing thereof, expenses, use of cash and otherresources, cost savings, capital requirements, and our needs for additional financing and our ability to obtain financingwhen needed;•future reimbursement and reimbursement rulings;•our business strategies, including our aim to focus on certain indications and the timing thereof;•the benefits of our products and services, including their ability to increase the probability of clinical trial success;•our ability to enter into and compete effectively in existing and new markets, with existing competitors and new marketentrants;•our ability to manage and grow our business by expanding our sales to existing customers or introducing our servicesand products to new customers;•our sales, marketing and commercialization plans and strategies, including